Preclinical characterization of a novel potent core protein assembly modulator for the treatment of chronic hepatitis B viral infection

• Published in: European journal of pharmaceutical sciences 2024-09, Vol.200, p.106834, Article 106834
• Main Authors: Dunkoksung, Wilasinee, Udomnilobol, Udomsak, Ruengsatra, Tanachote, Chauypen, Natthaya, Prueksaritanont, Thomayant
• Format: Article
• Language: English
• Subjects: Antiviral agents; Capsid assembly modulators; HBV core protein; Metabolism; Preclinical
• ISSN: 0928-0987; 1879-0720; 1879-0720
• DOI: 10.1016/j.ejps.2024.106834

The hepatitis B virus (HBV) capsid or core protein is a promising drug target currently being investigated for potential curative therapies for chronic HBV infection. In this study, we performed extensive in vitro and in vivo characterization of a novel and potent HBV core protein assembly modulator (CpAM), CU15, for both anti-HBV activity and druggability properties. CU15 potently inhibited HBV DNA replication in in vitro HBV-infected HepG2.2.15 cells (EC50 of 8.6 nM), with a low serum shift. It was also effective in inhibiting HBV DNA and cccDNA formation in de novo HBV-infected primary human hepatocytes. Furthermore, CU15 was active across several HBV genotypes and across clinically relevant core protein variants. After oral administration to an in vivo HBV mouse model, CU15 significantly reduced plasma HBV DNA and RNA levels, at plasma exposure consistent with the estimated in vitro potency. In vitro, CU15 exhibited excellent passive permeability and relatively high metabolic stability in liver preparations across species (human > dog> rat). In vitro human liver microsomal studies suggest that the compound's major metabolic pathway is CYP3A-mediated oxidation. Consistent with the in vitro findings, CU15 is a compound with a low-to-moderate clearance and high oral bioavailability in rats and dogs. Based on the apparent in vitro–in vivo correlation observed, CU15 has the potential to exhibit low clearance and high oral bioavailability in humans. In addition, CU15 also showed low drug–drug interaction liability with an acceptable in vitro safety profile (IC50 > 10 µM). [Display omitted]